venetoclax - Robuta Search

https://www.prnewswire.com/news-releases/biosight-launches-a-phase-12-clinical-trial-of-aspacytarabine-in-combination-with-venetoclax-for-first-line-aml-induction-therapy-followed-by-aspacytarabine-consolidation-301685067.html Biosight Launches a Phase 1/2 Clinical Trial of Aspacytarabine in Combination with Venetoclax for... /PRNewswire/ -- Biosight Ltd., a pharmaceutical development company developing innovative therapeutics for hematological malignancies and disorders, today... https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2024-01721&r=1 Revumenib and Venetoclax for the Treatment of Patients with Acute Myeloid Leukemia with Measurable... Revumenib and Venetoclax for the Treatment of Patients with Acute Myeloid Leukemia with Measurable Residual Disease https://pubmed.ncbi.nlm.nih.gov/38430306/ Successful use of Palbociclib combined with Venetoclax and Azacitidine in an adult with... Although only one successful case is presented here, three-drug combination regimens should be considered as another treatment option for t-AML in the future. https://adisinsight.springer.com/trials/700300717?error=cookies_not_supported&code=6d47d5df-5f7b-428f-bcd6-40a95257471c Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With Relapsed/Refractory... This study will evaluate the combined efficacy of venetoclax and ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia. followed by ibrutinib lead https://adisinsight.springer.com/drugsafety/803833731?error=cookies_not_supported&code=86db192c-47c1-46a2-8e15-4fbe7a3df73d Ibrutinib/venetoclax - AdisInsight A 74-year-old man received off-label treatment with ibrutinib and venetoclax for lymphocytic lymphoma [routes and not all dosages stated].The man was diagnosed ibrutinib venetoclax adisinsight https://adisinsight.springer.com/trials/700310743?error=cookies_not_supported&code=3fd8bb75-a64b-4e07-b070-3a4cf67638df A retrospective study to evaluate the safety and efficacy of venetoclax in patients with... This retrospective study evaluated the safety and efficacy of venetoclax in patients with immunoglobulin light chain (AL) amyloidosis. https://research.monash.edu/en/publications/concurrent-ibrutinib-plus-venetoclax-in-relapsedrefractory-mantle/ Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in... mantle cell lymphoma https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2023-10509 Revumenib, Azacitidine, and Venetoclax for the Treatment of Pediatric and Young Adult Patients with... Revumenib, Azacitidine, and Venetoclax for the Treatment of Pediatric and Young Adult Patients with Refractory or Relapsed Acute Myeloid Leukemia or Acute... https://pmc.ncbi.nlm.nih.gov/articles/PMC8997036/ Use of Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia: The PETHEMA... The use of venetoclax combined with hypomethylating agents or low-dose cytarabine in patients with newly diagnosed acute myeloid leukemia unfit for intensive... https://www.venclextahcp.com/ VENCLEXTA® (venetoclax tablets) AML & CLL/SLL Treatment HCP Site Select a VENCLEXTA® indication. VENCLEXTA is an oral therapy for select AML, CLL and SLL patients. See full safety and Prescribing Information for more details. venetoclax tablets aml cll sll https://adisinsight.springer.com/drugsafety/803927387?error=cookies_not_supported&code=6e8db03c-439e-4e7f-be3f-038aaf40e2b2 Ibrutinib/Venetoclax - AdisInsight Seventy-nine patients with relapsed or refractory chronic lymphocytic leukaemia in a phase II study received ibrutinib [dose and route not stated] for three ibrutinib venetoclax adisinsight https://adisinsight.springer.com/trials/700373106?error=cookies_not_supported&code=589e8de7-3409-4629-96ff-afb516cbeaa2 Multicenter, Open-label, Randomized, Phase 2 Study of Venetoclax and Azacitidine Plus Cusatuzumab... The goal of this clinical trial is to learn if participants treated with the experimental drug cusatuzumab added to venetoclax and azacitidine works to treat https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-of-venetoclax-and-azacitidine-for-acute-myeloid-leukaemia-viale-m A trial of venetoclax and azacitidine for acute myeloid leukaemia (VIALE M) This trial is comparing venetoclax and azacitidine with azacitidine for acute myeloid leukaemia (AML). acute myeloid leukaemia https://adisinsight.springer.com/drugsafety/803862809?error=cookies_not_supported&code=7d6533c8-a970-4354-9c66-3e731bf9db57 Azacitidine/venetoclax - AdisInsight In a retrospective study involving 33 patients with acute myeloid leukaemia who were treated between April 2016 and May 2023, 2 patients [ages and sexes not azacitidine venetoclax adisinsight https://adisinsight.springer.com/drugsafety/803491066?error=cookies_not_supported&code=a20ada6e-1fad-400a-bf6c-ef09f4431cb4 Posaconazole/venetoclax - AdisInsight A 16-year old boy developed febrile neutropenia following treatment with venetoclax for relapse of paediatric myelodysplastic syndrome (MDS)-related acute posaconazole venetoclax adisinsight https://adisinsight.springer.com/drugsafety/803928595?error=cookies_not_supported&code=c705105a-7443-49b0-87fd-6209949c835b Azacitidine/Tretinoin/Venetoclax - AdisInsight A 73-year-old patient [sex not stated] with acute myeloid leukaemia harbouring an AML1-MTG16 fusion and early molecular progression (burden 0.2%) received azacitidine tretinoin venetoclax adisinsight https://seer.cancer.gov/oncologytoolbox/canmed/hcpcs/1172/ venetoclax - CanMED: HCPCS CanMED: HCPCS. The Cancer Medications Enquiry Database (CanMED) is a two-part resource for cancer drug treatment related studies. venetoclax hcpcs https://pubmed.ncbi.nlm.nih.gov/41899121/ Disproportionality Analysis of Hematologic Adverse Event Signals Associated with Venetoclax in... adverse event associated with disproportionality analysis hematologic https://adisinsight.springer.com/trials/700375081?error=cookies_not_supported&code=f1237bca-f390-42ca-ab0d-a7c7f7737596 A Phase II Study of Venetoclax (ABT-199) in Combination With Cladribine and Low-Dose Cytarabine... This phase II trial tests how well venetoclax with cladribine and cytarabine alternating with azacitidine and venetoclax works in treating patients with newly https://pubmed.ncbi.nlm.nih.gov/39082439/ Clinical outcomes of hypomethylating agents and venetoclax in newly diagnosed unfit and... Venetoclax (VEN) combined with hypomethylating agents (HMA) decitabine or azacitidine is used for adult acute myeloid leukaemia (AML), but its application in... clinical outcomes newly diagnosed agents https://adisinsight.springer.com/drugsafety/803929909?error=cookies_not_supported&code=ebc9245d-f5c9-4b8e-97ba-371b8c18b0c5 Fms-like tyrosine kinase 3 inhibitors/Venetoclax - AdisInsight Three elderly patients [sex not stated; exact ages not stated] with relapsed or refractory FLT3-ITD-positive acute myeloid leukaemia experienced severe tyrosine kinase fms like inhibitors venetoclax https://www.mdpi.com/2077-0383/13/2/584 Real-Life Multicenter Experience of Venetoclax in Combination with Hypomethylating Agents in... Background: The landscape of first-line treatment for acute myeloid leukemia (AML) patients ineligible for intensive chemotherapy has changed remarkably after... real life multicenter experience https://cordis.europa.eu/project/id/101113342/results/pl Using ex vivo functional genomics as biomarker to predict the effectivity of Venetoclax in patients... Deliverables, publications, datasets, software, exploitable results https://pubmed.ncbi.nlm.nih.gov/36035991/ Protein Kinase CK2 represents a new target to boost Ibrutinib and Venetoclax induced cytotoxicity... Mantle cell lymphoma (MCL) is an incurable B cell non-Hodgkin lymphoma, characterized by frequent relapses. In the last decade, the pro-survival pathways... https://adisinsight.springer.com/drugsafety/803924269?error=cookies_not_supported&code=0ccf91a0-1fbf-40af-b44f-49f0d8362d6c Azacitidine/Venetoclax - AdisInsight A 60-year-old man with multi-refractory T-lymphoblastic lymphoma experienced lack of efficacy during treatment with venetoclax and azacitidine. The man azacitidine venetoclax adisinsight https://researchportal.helsinki.fi/sv/publications/erythroidmegakaryocytic-differentiation-confers-bcl-xl-dependency/ Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in... differentiation bcl https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2023-09679&r=1 A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) +... A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small... https://pubmed.ncbi.nlm.nih.gov/39949788/ Ibrutinib and venetoclax in combination for chronic lymphocytic leukemia: synergy in practice The combination of ibrutinib and venetoclax has emerged as a promising therapeutic strategy for patients with chronic lymphocytic leukemia (CLL). Preclinical... chronic lymphocytic leukemia ibrutinib venetoclax combination https://pmc.ncbi.nlm.nih.gov/articles/PMC11271855/ Vitamin K2 sensitizes the efficacy of venetoclax in acute myeloid leukemia by targeting the... Promising outcomes have been reported in elder patients with acute myeloid leukemia (AML) using combined therapy of venetoclax (VEN) and azacytidine (AZA) in... https://adisinsight.springer.com/drugsafety/803884244?error=cookies_not_supported&code=1a72c682-1547-4af3-b4a2-41d86ef6c2c1 Azacitidine/Venetoclax - AdisInsight In a retrospective study conducted between February 2017 to July 2023 involving 4 men aged 31-77 year-old were described who developed leukopenia, neutropenia, azacitidine venetoclax adisinsight https://pubmed.ncbi.nlm.nih.gov/28095146/ Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin... Purpose B-cell leukemia/lymphoma-2 (BCL-2) overexpression is common in many non-Hodgkin lymphoma (NHL) subtypes. A phase I trial in patients with NHL was... first in human study https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.890871/full Frontiers | MRD in Venetoclax-Based Treatment for AML: Does it Really Matter? The prognosis of newly diagnosed patients with acute myeloid leukemia (AML) is still unfavorable in the majority of cases within intermediate and mainly adv... treatment for https://pubmed.ncbi.nlm.nih.gov/33598678/ BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell... Conventional therapies for patients with T-cell prolymphocytic leukemia (T-PLL), such as cytotoxic chemotherapy and alemtuzumab, have limited efficacy and... https://adisinsight.springer.com/drugsafety/803926523?error=cookies_not_supported&code=99343d96-ed66-4310-b7f9-521a671b84b9 Venetoclax - AdisInsight An 80-year-old man with secondary acute myeloid leukaemia following chronic myelomonocytic leukaemia developed abrupt warm autoimmune haemolytic anaemia 4 days venetoclax adisinsight https://cordis.europa.eu/project/id/101113342/results/de Using ex vivo functional genomics as biomarker to predict the effectivity of Venetoclax in patients... Deliverables, publications, datasets, software, exploitable results https://researchprofiles.ku.dk/da/publications/venetoclax-plus-obinutuzumab-versus-chlorambucil-plus-obinutuzuma/ Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic... venetoclax plus obinutuzumab versus chlorambucil https://adisinsight.springer.com/drugsafety/803456225?error=cookies_not_supported&code=4a9e4076-4e6a-4592-9d45-48cbdebc659d Cytarabine/ivosidenib/venetoclax - AdisInsight A case series described, a 63-year-old man, who developed septic shock and multi-organ failure secondary to pulmonary Mycobacterium avium complex infection cytarabine venetoclax adisinsight https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b118a40d-6b56-cee3-10f6-ded821a97018 DailyMed - VENCLEXTA- venetoclax kit VENCLEXTA- venetoclax tablet, film coated dailymed venetoclax kit tablet film https://adisinsight.springer.com/trials/700392725?error=cookies_not_supported&code=4048a3de-53d1-4815-9a55-4d60a88146c6 A Phase 2 Study of Nemtabrutinib and Venetoclax as Frontline Treatment for Chronic Lymphocytic... This phase II trial tests how well nemtabrutinib and venetoclax work in treating patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2022-03312 SNDX-5613 with Decitabine/Cedazuridine, and Venetoclax for the Treatment of Relapsed or Refractory... SNDX-5613 with Decitabine/Cedazuridine, and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, SAVE Trial https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-of-venetoclax-with-low-dose-cytarabine-for-acute-myeloid-leukaemia-victor A trial of venetoclax with low dose cytarabine for acute myeloid leukaemia (VICTOR) This trial is comparing venetoclax and low dose cytarabine with intensive chemotherapy. It is for people with acute myeloid leukaemia aged 55 years and older. https://www.fda.gov/drugs/resources-information-approved-drugs/venetoclax-venclexta-tablets Venetoclax (Venclexta) Tablets | FDA venetoclax tablets fda https://adisinsight.springer.com/drugsafety/803850572?error=cookies_not_supported&code=00deabfa-bf28-462b-bc9b-9dc3bb2660cf Navitoclax/Venetoclax - AdisInsight In a retrospective, multicenter analysis, conducted between July 2019 and December 2022, two adult patients [sexes and exact ages not stated] were described, venetoclax adisinsight https://adisinsight.springer.com/trials/700303539?error=cookies_not_supported&code=26892838-1244-4d2b-8554-ed4c5107e24d Association between response to Venetoclax and Hypomethylating Agents therapy and leukemic somatic... The study evaluated the association bwetween response to Venetoclax and Hypomethylating Agents therapy and Prognostic Risk Groups and Genetic Subtypes of Acute association response venetoclax https://adisinsight.springer.com/trials/700391169?error=cookies_not_supported&code=6edfc0f4-190e-447c-baab-955a47983d33 A Phase 2 collaborative trial of revumenib in combination with venetoclax and azacitidine in newly... A Phase 2 collaborative trial of revumenib in combination with venetoclax and azacitidine in newly diagnosed KMT2Ar patients who would be considered eligible, https://connect.mayoclinic.org/discussion/does-anybody-take-venetoclax-for-cll/ Does anybody take Venetoclax for CLL? | Mayo Clinic Connect Does anybody with CLL take Venetoclax? mayo clinic anybody take venetoclax cll https://pubmed.ncbi.nlm.nih.gov/40524014/ The anti-CD47 antibody magrolimab with obinutuzumab and venetoclax in relapsed or refractory... Follicular lymphoma (FL), marginal zone lymphoma (MZL), chronic lymphocytic leukaemia (CLL) and mantle cell lymphoma (MCL) are characterized by a continuous... https://adisinsight.springer.com/drugsafety/803669103?error=cookies_not_supported&code=8f9fb0b4-f6d6-4690-805e-511d5619fb63 Azacitidine/venetoclax - AdisInsight In a case series, three patients [2 men and 1 women] aged 57-65 years were described, who exhibited lack of efficacy during treatment with venetoclax and azacitidine venetoclax adisinsight